---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-24-000056"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2024-10-10T23:59:59+00:00"
generated_at: "2026-05-30T16:28:31.555415+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Supernus to review Phase 2a data for SPN-820 in major depressive disorder on Oct 17

## Summary
- Company will host webcast and conference call on October 17, 2024 at 4:30 PM ET.
- Event will review data from open-label Phase 2a study of SPN-820 for major depressive disorder.
- No specific results are disclosed in this filing; data will be presented during the webcast.

## SEC filing metadata
- accession: 0001356576-24-000056
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2024-10-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657624000056/0001356576-24-000056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657624000056/supn-20241010.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-24-000056
- JSON: https://secwatch.observer/filing/0001356576-24-000056.json
- Plain text: https://secwatch.observer/filing/0001356576-24-000056.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.